Researchers at Boston Medical Center and Dana-Farber Cancer Institute conducted one of the first-ever analyses of neuroendocrine tumors (NETs) at single cell resolution, unlocking new insights into this rare and often hard-to-treat cancer.
German biotech’s efforts to revive obesity target for solid tumors yield positive PhIIa results
CatalYm’s solid tumor candidate, which targets a protein previously explored in obesity, has boosted responses in combination with an immune checkpoint inhibitor in an early-stage
December 7, 2023